VCNX
Vaccinex, Inc.
Price Chart
Latest Quote
$1.00
+0.23 (+29.44%)
Current Price
| Previous Close | $0.77 |
| Open | $1.00 |
| Day High | $1.00 |
| Day Low | $1.00 |
| Volume | 3,000 |
Stock Information
| Shares Outstanding | 2.68M |
| Total Debt | $25K |
| Cash Equivalents | $1.11M |
| Revenue | $601K |
| Net Income | $-18.63M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.68M |
| EPS (TTM) | $-8.88 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.65M |
| Sales | $601K |
| Income | $-18.63M |
| Book/sh | $-1.55 |
| Cash/sh | $0.41 |
| Employees | 23 |
Financial Ratios
| Quick Ratio | 0.38 |
| Current Ratio | 0.50 |
Returns & Margins
| ROA | -376.08% |
| Operating Margin | -1590.14% |
Ownership
| Insider Ownership | 11.48% |
| Institutional Ownership | 45.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.14 |
| P/S | 4.45 |
| P/B | -0.64 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.02 |
| SMA50 | $1.02 |
| SMA200 | $0.86 |
| RSI | 42.42 |
| ATR | 0.0543 |
| Shares Float | 1.18M |
| Short Float | 3.23% |
| Short Ratio | 0.60 |
| Volatility | 0.56 |
| Rel Volume | 1.03 |
Performance History
| Week | -0.01% |
| Month | -1.00% |
| Quarter | +63.92% |
| 6 Months | +49.24% |
| YTD | -11.51% |
| Year | +40.83% |
| 3 Years | -98.87% |
| 5 Years | -99.81% |
| 10 Years | -99.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $1.00 | 3,000 |
| 2026-06-03 | $0.77 | 2,200 |
| 2026-06-02 | $0.84 | 1,300 |
| 2026-06-01 | $1.00 | 0 |
| 2026-05-29 | $1.00 | 22,000 |
| 2026-05-28 | $1.00 | 11,900 |
| 2026-05-27 | $1.05 | 1,500 |
| 2026-05-26 | $1.05 | 500 |
| 2026-05-22 | $1.00 | 0 |
| 2026-05-21 | $1.00 | 2,000 |
| 2026-05-20 | $1.03 | 13,600 |
| 2026-05-19 | $1.10 | 0 |
| 2026-05-18 | $1.10 | 0 |
| 2026-05-15 | $1.10 | 0 |
| 2026-05-14 | $1.10 | 0 |
| 2026-05-13 | $1.10 | 0 |
| 2026-05-12 | $1.10 | 400 |
| 2026-05-11 | $1.01 | 0 |
| 2026-05-08 | $1.01 | 0 |
| 2026-05-07 | $1.01 | 0 |
| 2026-05-06 | $1.01 | 0 |
| 2026-05-05 | $1.01 | 0 |
| 2026-05-04 | $1.01 | 1,800 |
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on VCNX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $601,000 | $570,000 | $275,000 | $900,000 |
| Operating Revenue | $601,000 | $570,000 | $275,000 | $900,000 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Interest Expense | $2,000 | $1,000 | $2,000 | $809,000 |
| Total Expenses | $19,336,000 | $23,455,000 | $20,181,000 | $23,390,000 |
| Other Income Expense | $103,000 | $2,635,000 | $93,000 | $919,000 |
| Other Non Operating Income Expenses | $41,000 | $912,000 | $93,000 | $43,000 |
| Net Non Operating Interest Income Expense | $-2,000 | $-1,000 | $-2,000 | $-809,000 |
| Interest Expense Non Operating | $2,000 | $1,000 | $2,000 | $809,000 |
| Operating Expense | $19,336,000 | $23,455,000 | $20,181,000 | $23,390,000 |
| General And Administrative Expense | $6,791,000 | $6,881,000 | $6,202,000 | $6,230,000 |
| Other Operating Expenses | - | - | $-175,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Net Interest Income | $-2,000 | $-1,000 | $-2,000 | $-809,000 |
| Normalized Income | $-18,696,000 | $-21,974,000 | $-19,815,000 | $-23,256,000 |
| Net Income From Continuing And Discontinued Operation | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Total Operating Income As Reported | $-18,735,000 | $-22,885,000 | $-19,906,000 | $-22,490,000 |
| Net Income Common Stockholders | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Net Income | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Net Income Including Noncontrolling Interests | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Net Income Continuous Operations | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Pretax Income | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Operating Income | $-18,735,000 | $-22,885,000 | $-19,906,000 | $-22,490,000 |
| Special Income Charges | - | - | $0 | $876,000 |
| Gross Profit | - | - | - | $900,000 |
| Per Share | ||||
| Diluted EPS | - | $-43.68 | $-98.05 | $-163.80 |
| Basic EPS | - | $-43.68 | $-98.05 | $-163.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,600,000 | $-21,854,000 | $-19,606,000 | $-22,278,000 |
| Total Unusual Items | $62,000 | $1,723,000 | $0 | $876,000 |
| Total Unusual Items Excluding Goodwill | $62,000 | $1,723,000 | $0 | $876,000 |
| Reconciled Depreciation | $94,000 | $119,000 | $207,000 | $169,000 |
| EBITDA (Bullshit earnings) | $-18,538,000 | $-20,131,000 | $-19,606,000 | $-21,402,000 |
| EBIT | $-18,632,000 | $-20,250,000 | $-19,813,000 | $-21,571,000 |
| Diluted NI Availto Com Stockholders | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $62,000 | $1,723,000 | - | - |
| Research And Development | $12,545,000 | $16,574,000 | $13,979,000 | $17,160,000 |
| Selling General And Administration | $6,791,000 | $6,881,000 | $6,202,000 | $6,230,000 |
| Other Gand A | $6,791,000 | $6,881,000 | $6,202,000 | $6,230,000 |
| Diluted Average Shares | - | $463,653 | $202,082 | $137,377 |
| Basic Average Shares | - | $463,653 | $202,082 | $137,377 |
| Minority Interests | - | - | - | $0 |
| Other Special Charges | - | - | - | $-876,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,488,000 | $-2,311,000 | $5,193,000 | $7,412,000 |
| Total Assets | $2,596,000 | $3,631,000 | $7,977,000 | $9,843,000 |
| Total Non Current Assets | $65,000 | $283,000 | $499,000 | $438,000 |
| Current Assets | $2,531,000 | $3,349,000 | $7,478,000 | $9,405,000 |
| Other Current Assets | $586,000 | $853,000 | $912,000 | $816,000 |
| Hedging Assets Current | $0 | $0 | - | - |
| Receivables | $838,000 | $961,000 | $175,000 | $0 |
| Accounts Receivable | $838,000 | $961,000 | $175,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $1,107,000 | $1,535,000 | $6,391,000 | $8,589,000 |
| Cash And Cash Equivalents | $1,107,000 | $1,535,000 | $6,391,000 | $8,589,000 |
| Prepaid Assets | - | - | - | $816,000 |
| Debt | ||||
| Total Debt | $25,000 | $247,000 | $485,000 | $390,000 |
| Current Debt And Capital Lease Obligation | $25,000 | $221,000 | $238,000 | $215,000 |
| Current Debt | $25,000 | $75,000 | $74,000 | $74,000 |
| Other Current Borrowings | $25,000 | $75,000 | $74,000 | $74,000 |
| Long Term Debt And Capital Lease Obligation | - | $26,000 | $247,000 | $175,000 |
| Long Term Debt | - | $26,000 | $101,000 | $175,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,084,000 | $5,942,000 | $2,784,000 | $2,431,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $26,000 | $247,000 | $175,000 |
| Current Liabilities | $5,084,000 | $5,916,000 | $2,537,000 | $2,256,000 |
| Current Deferred Liabilities | $0 | $63,000 | $0 | - |
| Payables And Accrued Expenses | $5,059,000 | $3,281,000 | $2,299,000 | $2,041,000 |
| Payables | $3,955,000 | $2,039,000 | $1,518,000 | $1,061,000 |
| Accounts Payable | $3,955,000 | $2,039,000 | $1,518,000 | $1,061,000 |
| Other Current Liabilities | - | $2,351,000 | - | - |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-4,153,000 | $-2,311,000 | $5,193,000 | $7,412,000 |
| Preferred Stock Equity | $1,665,000 | - | - | - |
| Total Equity Gross Minority Interest | $-2,488,000 | $-2,311,000 | $5,193,000 | $7,412,000 |
| Stockholders Equity | $-2,488,000 | $-2,311,000 | $5,193,000 | $7,412,000 |
| Retained Earnings | $-358,561,000 | $-339,927,000 | $-319,676,000 | $-299,861,000 |
| Other | ||||
| Treasury Shares Number | $5 | $4 | $4 | $4 |
| Ordinary Shares Number | $2,676,637 | $892,616 | $237,527 | $146,671 |
| Share Issued | $2,676,642 | $892,620 | $237,531 | $146,675 |
| Tangible Book Value | $-4,153,000 | $-2,311,000 | $5,193,000 | $7,412,000 |
| Invested Capital | $-4,128,000 | $-2,210,000 | $5,368,000 | $7,661,000 |
| Working Capital | $-2,553,000 | $-2,567,000 | $4,941,000 | $7,149,000 |
| Capital Lease Obligations | $0 | $146,000 | $310,000 | $141,000 |
| Total Capitalization | $-2,488,000 | $-2,285,000 | $5,294,000 | $7,587,000 |
| Treasury Stock | $11,000 | $11,000 | $11,000 | $11,000 |
| Additional Paid In Capital | $354,418,000 | $337,627,000 | $324,880,000 | $307,281,000 |
| Capital Stock | $1,666,000 | $0 | $0 | $3,000 |
| Common Stock | $1,000 | $0 | $0 | $3,000 |
| Preferred Stock | $1,665,000 | $0 | - | - |
| Current Deferred Revenue | $0 | $63,000 | $0 | - |
| Current Capital Lease Obligation | $0 | $146,000 | $164,000 | $141,000 |
| Current Accrued Expenses | $1,104,000 | $1,242,000 | $781,000 | $980,000 |
| Net PPE | $65,000 | $283,000 | $499,000 | $438,000 |
| Accumulated Depreciation | $-7,185,000 | $-7,091,000 | $-7,256,000 | $-7,049,000 |
| Gross PPE | $7,250,000 | $7,374,000 | $7,755,000 | $7,487,000 |
| Leases | $3,277,000 | $3,277,000 | $3,259,000 | $3,213,000 |
| Other Properties | $3,373,000 | $3,497,000 | $3,825,000 | $3,640,000 |
| Machinery Furniture Equipment | $600,000 | $600,000 | $671,000 | $634,000 |
| Properties | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | $0 | $146,000 | $0 |
| Minority Interest | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,208,000 | $-21,446,000 | $-19,173,000 | $-25,330,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,186,000 | $-21,379,000 | $-19,074,000 | $-25,298,000 |
| Cash Flow From Continuing Operating Activities | $-16,186,000 | $-21,379,000 | $-19,074,000 | $-25,298,000 |
| Operating Gains Losses | $1,201,000 | $67,000 | - | $-876,000 |
| Investing Activities | ||||
| Capital Expenditure | $-22,000 | $-67,000 | $-99,000 | $-32,000 |
| Investing Cash Flow | $-22,000 | $-67,000 | $-99,000 | $-32,000 |
| Cash Flow From Continuing Investing Activities | $-22,000 | $-67,000 | $-99,000 | $-32,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,822,000 | $12,273,000 | $17,050,000 | $32,848,000 |
| Financing Cash Flow | $15,780,000 | $16,590,000 | $16,975,000 | $23,323,000 |
| Cash Flow From Continuing Financing Activities | $15,780,000 | $16,590,000 | $16,975,000 | $23,323,000 |
| Net Preferred Stock Issuance | $1,697,000 | $0 | - | - |
| Preferred Stock Issuance | $1,697,000 | $0 | - | - |
| Net Common Stock Issuance | $7,125,000 | $12,273,000 | $17,050,000 | $32,848,000 |
| Common Stock Issuance | $7,125,000 | $12,273,000 | $17,050,000 | $32,848,000 |
| Net Other Financing Charges | - | - | - | $-985,000 |
| Other | ||||
| Repayment Of Debt | $-76,000 | $-74,000 | $-75,000 | $-8,540,000 |
| End Cash Position | $1,107,000 | $1,535,000 | $6,391,000 | $8,589,000 |
| Beginning Cash Position | $1,535,000 | $6,391,000 | $8,589,000 | $10,596,000 |
| Changes In Cash | $-428,000 | $-4,856,000 | $-2,198,000 | $-2,007,000 |
| Proceeds From Stock Option Exercised | $7,034,000 | $4,391,000 | - | $0 |
| Net Issuance Payments Of Debt | $-76,000 | $-74,000 | $-75,000 | $-8,540,000 |
| Net Long Term Debt Issuance | $-76,000 | $-74,000 | $-75,000 | $-8,540,000 |
| Long Term Debt Payments | $-76,000 | $-74,000 | $-75,000 | $-8,540,000 |
| Net PPE Purchase And Sale | $-22,000 | $-67,000 | $-99,000 | $-32,000 |
| Purchase Of PPE | $-22,000 | $-67,000 | $-99,000 | $-32,000 |
| Change In Working Capital | $2,103,000 | $318,000 | $-11,000 | $-3,210,000 |
| Change In Other Working Capital | $-63,000 | $63,000 | - | - |
| Change In Payables And Accrued Expense | $1,776,000 | $982,000 | $258,000 | $-3,065,000 |
| Change In Accrued Expense | $-138,000 | $461,000 | $-199,000 | $-957,000 |
| Change In Payable | $1,914,000 | $521,000 | $457,000 | $-2,108,000 |
| Change In Account Payable | $1,914,000 | $521,000 | $457,000 | $-2,108,000 |
| Change In Prepaid Assets | $267,000 | $59,000 | $-94,000 | $-302,000 |
| Change In Receivables | $123,000 | $-786,000 | $-175,000 | $157,000 |
| Changes In Account Receivables | $123,000 | $-786,000 | $-175,000 | $157,000 |
| Other Non Cash Items | $-1,291,000 | $-2,106,000 | - | $458,000 |
| Stock Based Compensation | $341,000 | $474,000 | $545,000 | $541,000 |
| Depreciation Amortization Depletion | $94,000 | $119,000 | $207,000 | $169,000 |
| Depreciation And Amortization | $94,000 | $119,000 | $207,000 | $169,000 |
| Depreciation | $94,000 | $119,000 | $207,000 | $169,000 |
| Gain Loss On Investment Securities | $1,201,000 | $67,000 | - | - |
| Net Income From Continuing Operations | $-18,634,000 | $-20,251,000 | $-19,815,000 | $-22,380,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-02-02